KRYSTAL SHELTON: Open Payments
NPI 1992331573 · PARKER, CO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$711 in 27 payments from 12 companies in 2025. Trend: 2023 $1,320 · 2024 $1,074 · 2025 $711
Food & beverage: $711
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 5 | $177 |
| Teva Pharmaceuticals USA, Inc. | 2 | $139 |
| Neurocrine BioSciences, Inc. | 3 | $74 |
| Axsome Therapeutics, Inc. | 3 | $69 |
| Otsuka America Pharmaceutical, Inc. | 3 | $54 |
| ABBVIE INC. | 2 | $38 |
| Lundbeck LLC | 2 | $36 |
| Vanda Pharmaceuticals Inc. | 1 | $35 |
| Alkermes, Inc. | 2 | $34 |
| E.R. Squibb & Sons, L.L.C. | 2 | $31 |
Products named: CAPLYTA, AUSTEDO XR, REXULTI, INGREZZA, Auvelity, VRAYLAR, FANAPT, UZEDY.
Industry payments across CO — which companies pay providers there.
